Clinical Trials Browser

Completed × Everolimus × Clear all

NCT01167530 2026-04-06

RAD001

Phase 1 Completed

Carcinoma, Non-Small-Cell Lung

NCT02184416 2026-02-27

ADONIS

Carcinoma, Renal Cell

NCT02520063 2026-02-06

Combination of Letrozole, Everolimus and TRC105 in Postmenopausal Women With Hormone-Receptor Positive and Her2 Negative Breast Cancer

Phase 1/2 Completed

15 enrolled 18 charts

Breast Neoplasms

NCT02407509 2026-01-29

RAF/MEK

Phase 1 Completed

GynecologicPlasma cellThoracic

Lung Neoplasms, Multiple Myeloma, Ovarian Neoplasms

NCT00799188 2025-12-19

CERTICOEUR

Phase 3 Completed

Skin Neoplasms

NCT01582191 2025-10-27

Vandetanib and Everolimus in Treating Patients With Advanced or Metastatic Cancer

Phase 1 Completed

Neoplasm Metastasis, Neoplasms, Recurrence

NCT05501769 2025-09-26

TACTIVE-E

Phase 1 Completed

Breast Neoplasms

NCT01120249 2025-09-16

S0931

Phase 3 Completed

1,545 enrolled 15 charts

Carcinoma, Renal Cell, Kidney Neoplasms

NCT03112603 2025-08-12

A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)

Phase 3 Completed

330 enrolled 32 charts 2 FDA

Bronchiolitis Obliterans Syndrome, Graft vs Host Disease

NCT02123823 2025-07-15

BI 836845 in Estrogen Receptor Positive Metastatic Breast Cancer

Phase 1 Completed

164 enrolled 21 charts

Neoplasms

NCT03834740 2025-05-30

A Phase 0/I Study of Ribociclib (LEE011) in Combination With Everolimus in Preoperative Recurrent High-Grade Glioma Patients Scheduled for Resection

Phase EARLY_PHASE1 Completed

27 enrolled 17 charts

Brain Neoplasms, Glioblastoma, Glioma

NCT02246127 2025-05-11

SEQTOR

Phase 3 Completed

141 enrolled 27 charts

Neuroendocrine Tumors

NCT00087685 2025-05-01

RAD001 in Recurrent Endometrial Cancer Patients

Phase 2 Completed

35 enrolled 6 charts

Uterine Neoplasms, Endometrial Neoplasms

NCT00113360 2025-05-01

RAD001 Plus Octreotide Depot in Metastatic or Unresectable Low Grade Neuroendocrine Carcinoma

Phase 2 Completed

67 enrolled 6 charts

Carcinoma, Islet Cell, Carcinoma, Neuroendocrine

NCT00449748 2025-05-01

Everolimus (RAD001) as Therapy for Patients With Systemic Mastocytosis

Phase 2 Completed

10 enrolled 4 charts

Mastocytosis, Systemic

NCT00942734 2025-05-01

Trial of RAD001 and Erlotinib With Recurrent Head and Neck Squamous Cell Carcinoma

Phase 2 Completed

49 enrolled 5 charts

Carcinoma, Squamous Cell, Head and Neck Neoplasms

NCT00317720 2025-04-30

Trastuzumab and RAD001 in Patients With Human Epidermal Growth Receptor 2 (HER-2) Overexpressing Breast Cancer

Phase 1/2 Completed

40 enrolled 8 charts

Breast Neoplasms, Neoplasm Metastasis

NCT00081874 2025-04-27

RAD001 in Relapsed or Refractory AML, ALL, CML in Blastic-Phase, Agnogenic Myeloid Metaplasia, CLL, T-Cell Leukemia, or Mantle Cell Lymphoma

Phase 1/2 Completed

LymphoidMyeloidOther hematologic neoplasm

Leukemia, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, T-Cell, Leukemia, Myeloid, Acute, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Primary Myelofibrosis

NCT03324373 2025-04-24

Lenvatinib and Everolimus in Renal Cell Carcinoma (RCC)

Phase 1 Completed

Carcinoma, Renal Cell

NCT04339062 2025-04-23

CONTRAC

Phase 1/2 Completed

12 enrolled 13 charts

Cutaneous Squamous Cell Carcinoma

NCT03173560 2025-04-01

Trial to Assess Safety and Efficacy of Lenvatinib (18 mg vs. 14 mg) in Combination With Everolimus in Participants With Renal Cell Carcinoma

Phase 2 Completed

343 enrolled 25 charts

Carcinoma, Renal Cell

NCT03659136 2025-02-24

The XENERA™ 1 Study Tests Xentuzumab in Combination With Everolimus and Exemestane in Women With Hormone Receptor Positive and HER2-negative Breast Cancer That Has Spread

Phase 2 Completed

103 enrolled 16 charts

Breast Neoplasms

NCT02531932 2025-02-19

Comparison of Single-Agent Carboplatin vs the Combination of Carboplatin and Everolimus for the Treatment of Advanced Triple-Negative Breast Cancer

Phase 2 Completed

Breast Neoplasms

NCT02991807 2025-02-17

RAD001 and Neurocognition in PTEN Hamartoma Tumor Syndrome

Phase 1/2 Completed

46 enrolled 15 charts

Autistic Disorder, Hamartoma Syndrome, Multiple, Intellectual Disability

NCT02842749 2025-02-10

Phase IV Study of the Safety and Efficacy of Everolimus in Adult Patients With Progressive pNET in China

Phase 4 Completed

61 enrolled 9 charts

EndocrineGastrointestinalNET

Pancreatic Neuroendocrine Tumors

NCT04818632 2024-12-17

AZD9833

Phase 1 Completed

Breast Neoplasms

NCT02216786 2024-12-02

MANTA

Phase 2 Completed

Estrogen Receptor Positive Breast Cancer

NCT03070301 2024-10-10

A Study of LEE011 With Everolimus in Patients With Advanced Neuroendocrine Tumors

Phase 2 Completed

21 enrolled 8 charts

Neuroendocrine Tumors

NCT01678664 2024-09-25

EVACEL

Phase 2 Completed

74 enrolled 10 charts

Neoplasm Metastasis, Neoplasms, Neuroendocrine Tumors

NCT02228681 2024-09-19

Everolimus and Letrozole or Hormonal Therapy to Treat Endometrial Cancer

Phase 2 Completed

74 enrolled 13 charts

Advanced, Persistent, or Recurrent Endometrial Cancer

NCT00655655 2024-08-21

Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors

Phase 1 Completed

DermatologicEndocrineGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Glucagonoma, Insulinoma, Melanoma, Pheochromocytoma, Somatostatinoma, Carcinoma, Merkel Cell, Gastrinoma, Carcinoma, Islet Cell, Carcinoma, Medullary

NCT03154281 2024-08-01

Evaluation of the Safety and Tolerability of Niraparib With Everolimus in Advanced Gynecologic Malignancies and Breast

Phase 1 Completed

14 enrolled 12 charts

BreastGynecologic

Breast Neoplasms, Ovarian Neoplasms

NCT01523977 2024-07-18

CRAD001NUS175T

Phase 1 Completed

LymphoidOther hematologic neoplasm

Recurrence, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02155920 2024-05-08

Everolimus for Children With Recurrent or Progressive Ependymoma

Phase 2 Completed

11 enrolled 13 charts

Familial ependymoma, Ependymoma

NCT02456857 2024-02-13

Liposomal Doxorubicin, Bevacizumab, and Everolimus in Patients With Locally Advanced TNBC With Tumors Predicted Insensitive to Standard Chemotherapy; A Moonshot Initiative

Phase 2 Completed

17 enrolled 8 charts

Triple Negative Breast Neoplasms

NCT03312738 2024-01-23

BOLERO-5

Phase 2 Completed

159 enrolled 25 charts

Breast Neoplasms

NCT02332902 2023-12-20

DCLNF1

Phase 2 Completed

24 enrolled 4 charts

Neurofibroma, Neurofibromatosis 1

NCT02258451 2023-11-24

Study of Radium-223 Dichloride in Combination With Exemestane and Everolimus Versus Placebo in Combination With Exemestane and Everolimus in Subjects With Bone Predominant HER2 Negative Hormone Receptor Positive Metastatic Breast Cancer

Phase 2 Completed

283 enrolled 22 charts

Breast Neoplasms

NCT02599324 2023-11-18

Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors

Phase 1/2 Completed

263 enrolled 34 charts

Carcinoma, Renal Cell

NCT02264665 2023-11-13

OPALINE

144 enrolled 26 charts

Adenoma, Islet Cell

NCT01827384 2023-09-29

MPACT Study to Compare Effects of Targeted Drugs on Tumor Gene Variations

Phase 2 Completed

208 enrolled 27 charts

Other solid neoplasm

Advanced Malignant Solid Neoplasm

NCT01298713 2023-09-06

Tamoxifen-RAD001 Versus Tamoxifen Alone in Patients With Anti-aromatase Resistant Breast Metastatic Cancer

Phase 2 Completed

Breast Neoplasms

NCT03245151 2023-08-30

Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric Solid Tumors, Including Central Nervous System Tumors

Phase 1/2 Completed

64 enrolled 29 charts

Glioma, Recurrence, Rhabdomyosarcoma, Central Nervous System Neoplasms, Neuroectodermal Tumors, Primitive, Peripheral

NCT02028364 2023-08-24

PEARL

Phase 2 Completed

Breast Neoplasms

NCT00255788 2023-08-04

Everolimus in Treating Patients WIth Recurrent or Metastatic Breast Cancer

Phase 2 Completed

Breast Neoplasms, Breast Neoplasms, Male

NCT00387400 2023-08-04

Temozolomide + Everolimus in Newly Diagnosed, Recurrent, or Progressive Malignant Glioblastoma Multiforme

Phase 1 Completed

Brain Neoplasms, Glioblastoma, Central Nervous System Neoplasms, Gliosarcoma

NCT03328104 2023-07-21

ENCERT

Phase 1 Completed

LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT01430572 2023-06-06

Pazopanib and Everolimus in PI3KCA Mutation Positive/PTEN Loss Patients

Phase 1 Completed

Other solid neoplasm

Advanced Cancers

NCT02106507 2023-05-26

ARN 509 Plus Everolimus in Men With Progressive Metastatic Castration-Resistant Prostate Cancer After Treatment With Abiraterone Acetate

Phase 1 Completed

Prostatic Neoplasms

NCT02333565 2023-05-25

CEVOREM

Phase 2 Completed

Meningioma